L. Hettrick

Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice.

P. Adamson, B. Monia, S. Henry, 2016, Immunobiology.

Comparative bioavailability of L-683,453, a 5α-reductase inhibitor, from a self-emulsifying drug delivery system in Beagle dogs

D. Storey, B. Matuszewska, L. Hettrick, 1996 .

Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists.

M. Bock, R. Freidinger, R. Chang, 2006, Journal of medicinal chemistry.

The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.

Gloria Kwei, Udit Batra, D. Storey, 2004, International journal of pharmaceutics.

Regiospecific Intestinal Absorption of the HIV Protease Inhibitor L-735,524 in Beagle Dogs

Gloria Kwei, I. Chen, G. Kwei, 1995, Pharmaceutical Research.

Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide

B. Monia, S. Henry, T. R. Grossman, 2016, Molecular vision.

Abstract 5561: High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T-cells and produce antitumor effects in syngeneic tumor models

S. Barry, P. Lyne, A. Macleod, 2018, Clinical research.